DRREDDY Stock View

Dr Reddys Laboratories Ltd
stock-view-header

₹ 5,517.05

icon -136.65 | -2.41
Market Cap ₹( Cr.)
918,253.40
Proj. P/E (x)
19.64
Proj. P/BV (x)
3.39
Proj. ROE (%)
17.97
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)
270,994.26

Stock View

HOLD

Last Updated On.
17-Sep-2023
 

The average score for Dr Reddys Laboratories Ltd stands at 10 against 8, three months back.

Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
5,620.84
100 DMA(₹)
5,202.18
200 DMA(₹)
4,833.01
52 Weeks Range
4,088.70     5,986.20

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required